187 A LIQUID BIOPSY EXOSOMAL MICRORNA PANEL FOR PREDICTING RECURRENCE FOLLOWING SURGERY IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA

2021 ◽  
Vol 160 (6) ◽  
pp. S-46
Author(s):  
Satoshi Nishiwada ◽  
Ya Cui ◽  
Masayuki Sho ◽  
Eunsung Jun ◽  
Takahiro Akahori ◽  
...  
Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1656 ◽  
Author(s):  
Etienne Buscail ◽  
Catherine Alix-Panabières ◽  
Pascaline Quincy ◽  
Thomas Cauvin ◽  
Alexandre Chauvet ◽  
...  

Purpose: Expediting the diagnosis of pancreatic ductal adenocarcinoma (PDAC) would benefit care management, especially for the start of treatments requiring histological evidence. This study evaluated the combined diagnostic performance of circulating biomarkers obtained by peripheral and portal blood liquid biopsy in patients with resectable PDAC. Experimental design: Liquid biopsies were performed in a prospective translational clinical trial (PANC-CTC #NCT03032913) including 22 patients with resectable PDAC and 28 noncancer controls from February to November 2017. Circulating tumor cells (CTCs) were detected using the CellSearch® method or after RosetteSep® enrichment combined with CRISPR/Cas9-improved KRAS mutant alleles quantification by droplet digital PCR. CD63 bead-coupled Glypican-1 (GPC1)-positive exosomes were quantified by flow cytometry. Results: Liquid biopsies were positive in 7/22 (32%), 13/22 (59%), and 14/22 (64%) patients with CellSearch® or RosetteSep®-based CTC detection or GPC1-positive exosomes, respectively, in peripheral and/or portal blood. Liquid biopsy performance was improved in portal blood only with CellSearch®, reaching 45% of PDAC identification (5/11) versus 10% (2/22) in peripheral blood. Importantly, combining CTC and GPC1-positive-exosome detection displayed 100% of sensitivity and 80% of specificity, with a negative predictive value of 100%. High levels of GPC1+-exosomes and/or CTC presence were significantly correlated with progression-free survival and with overall survival when CTC clusters were found. Conclusion: This study is the first to evaluate combined CTC and exosome detection to diagnose resectable pancreatic cancers. Liquid biopsy combining several biomarkers could provide a rapid, reliable, noninvasive decision-making tool in early, potentially curable pancreatic cancer. Moreover, the prognostic value could select patients eligible for neoadjuvant treatment before surgery. This exploratory study deserves further validation.


2021 ◽  
Vol Volume 14 ◽  
pp. 2163-2175
Author(s):  
Huilin Shao ◽  
Yue Zhang ◽  
Jie Yan ◽  
Xinchao Ban ◽  
Xiaojie Fan ◽  
...  

2020 ◽  
Vol 158 (6) ◽  
pp. S-857
Author(s):  
SOUVIK GHATAK ◽  
Satoshi Nishiwada ◽  
Eunsung Jun ◽  
Fuminori Sonohara ◽  
Yasuhiro Kodera ◽  
...  

2019 ◽  
Vol 156 (6) ◽  
pp. S-326-S-327
Author(s):  
Hiroyuki Terasawa ◽  
Hideaki Kinugasa ◽  
Kazuhiro Nouso ◽  
Soichiro Ako ◽  
Mami Hirai ◽  
...  

2019 ◽  
Vol 20 (10) ◽  
pp. 1348-1353 ◽  
Author(s):  
Hiroyuki Terasawa ◽  
Hideaki Kinugasa ◽  
Soichiro Ako ◽  
Mami Hirai ◽  
Hiroshi Matsushita ◽  
...  

2021 ◽  
Vol 22 (12) ◽  
pp. 6501
Author(s):  
Violeta Morcuende-Ventura ◽  
Sonia Hermoso-Durán ◽  
Natalia Abian-Franco ◽  
Roberto Pazo-Cid ◽  
Jorge L. Ojeda ◽  
...  

(1) Background: Biophysical techniques applied to serum samples characterization could promote the development of new diagnostic tools. Fluorescence spectroscopy has been previously applied to biological samples from cancer patients and differences from healthy individuals were observed. Dendronized hyperbranched polymers (DHP) based on bis(hydroxymethyl)propionic acid (bis-MPA) were developed in our group and their potential biomedical applications explored. (2) Methods: A total of 94 serum samples from diagnosed cancer patients and healthy individuals were studied (20 pancreatic ductal adenocarcinoma, 25 blood donor, 24 ovarian cancer, and 25 benign ovarian cyst samples). (3) Results: Fluorescence spectra of serum samples (fluorescence liquid biopsy, FLB) in the presence and the absence of DHP-bMPA were recorded and two parameters from the signal curves obtained. A secondary parameter, the fluorescence spectrum score (FSscore), was calculated, and the diagnostic model assessed. For pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer, the classification performance was improved when including DHP-bMPA, achieving high values of statistical sensitivity and specificity (over 85% for both pathologies). (4) Conclusions: We have applied FLB as a quick, simple, and minimally invasive promising technique in cancer diagnosis. The classification performance of the diagnostic method was further improved by using DHP-bMPA, which interacted differentially with serum samples from healthy and diseased subjects. These preliminary results set the basis for a larger study and move FLB closer to its clinical application, providing useful information for the oncologist during patient diagnosis.


2022 ◽  
Vol 8 ◽  
Author(s):  
Daniel C. Osei-Bordom ◽  
Gagandeep Sachdeva ◽  
Niki Christou

Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments.


Sign in / Sign up

Export Citation Format

Share Document